Additional anticoagulant strategies for managing heparin-induced thrombocytopenia.
Nawarskas
J J
JJ
Spinler
S A
SA
D000925:Anticoagulants / Q000009:adverse effects*; D000991:Antithrombins / Q000494:pharmacology*; D001120:Arginine / Q000031:analogs & derivatives; D002809:Chondroitin Sulfates / Q000494:pharmacology; D003871:Dermatan Sulfate / Q000494:pharmacology; D004338:Drug Combinations; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000494:pharmacology; D010875:Pipecolic Acids / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000145:classification / Q000517:prevention & control*
D000925:Anticoagulants; D000991:Antithrombins; D001120:Arginine; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; C035838:danaparoid; C031942:argatroban